/
SENS
$5.94+$0.22 (+3.85%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$298.6M
52M shares
52-week range
$4.79 – $12.58
15% from low
Sector
INDUSTRIAL INSTRUMENTS FOR MEASUREMENT, DISPLAY, AND CONTROL
Exchange
NASDAQ
CS
Borrow rate
1.40%
Moderate
Price (6 mo)
Loading chart…
Change$-70.86
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $18.9M | $21.3M | $4.9M | $13.7M | $16.4M | $22.4M | $22.5M | $35.3M |
| Cost of revenue | $27.1M | $40.7M | $22.3M | $14.5M | $13.7M | $19.3M | $21.9M | $19.5M |
| Gross profit | −$8.1M | −$19.4M | −$17.4M | −$811.0K | $2.7M | $3.1M | $533.0K | $15.8M |
| Gross margin | -43.1% | -91.3% | -350.9% | -5.9% | 16.6% | 13.8% | 2.4% | 44.7% |
| R&D | $31.9M | $38.4M | $20.4M | $27.2M | $39.7M | $48.8M | $41.1M | $31.6M |
| Operating income | −$87.6M | −$130.7M | −$79.1M | −$57.2M | −$68.6M | −$75.6M | −$74.8M | −$68.3M |
| EBITDA | −$85.4M | −$99.4M | −$157.9M | −$284.5M | $161.8M | −$48.0M | −$68.7M | −$62.6M |
| Net income | −$94.0M | −$115.5M | −$175.2M | −$302.5M | $142.1M | −$60.4M | −$78.6M | −$69.1M |
| Net margin | -496.9% | -542.5% | -3539.5% | -2211.9% | 867.2% | -269.7% | -349.8% | -196.0% |
| EPS (diluted) | -12.00 | -12.20 | -15.40 | -14.40 | -2.17 | -2.20 | -2.50 | -1.66 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $62M | $-2.40 | $-2.77–$-2.11 | 5 |
| 2027 | $98M | $-2.15 | $-2.73–$-1.92 | 5 |
| 2028 | $125M | $-1.57 | $-2.08–$-1.15 | 4 |
| 2029 | $171M | $-0.96 | $-1.12–$-0.89 | 2 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
Senseonics Holdings, Inc. Common Stock
Senseonics Holdings Inc is a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system to improve the lives of people with diabetes by enhancing their ability to manage their disease with relative ease and accuracy. Its implantable CGM system, Eversense, including Eversense E3 and Eversense 365 CGM systems, measures glucose levels via an under-the-skin sensor, a removable and rechargeable smart transmitter, and an app for real-time diabetes monitoring and management. The company operates through one reportable segment which derives its revenues from diabetes products and services and generates the majority of its revenue from the United States.
www.senseonics.com- Employees
- 130
- IPO / List date
- Mar 18, 2016
- HQ
- GERMANTOWN, MD
Held by traders on TradeandTell
No one on the platform currently holds SENS.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in SENS as of their last filing.
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2025-10-20 | 1-for-20reverse |
Recent trades on TradeandTell
No one on the platform has traded SENS yet.
